Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination | TEDCO

Trial funded in part by a grant from Maryland Technology Development Corporation (TEDCO) and the National Institute on Aging (NIA) of the National Institutes of Health (NIH)

URL

http://www.globenewswire.com/news-release/2021/04/15/2210839/0/en/Longeveron-Announces-Successful-Completion-of-Phase-I-II-Clinical-Study-of-Lomecel-B-Infusion-in-Aging-Frailty-Subjects-to-Improve-Immune-Response-Following-Influenza-Vaccination.html

Companies

About TEDCO

On

Release date

Thu, 04/15/2021 - 12:00

Funds

Maryland Stem Cell Research Fund